Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches

Molecular Oncology

Volumn 9, Issue 5, 2015, Pages 1008-1017

  Serrano, Davide ^a   Lazzeroni, Matteo ^a   Bonanni, Bernardo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Chemoprevention; Surrogate biomarkers; Vaccines

Indexed keywords

ACETYLSALICYLIC ACID; AROMATASE INHIBITOR; CELECOXIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; METFORMIN; MUCIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VITAMIN D DERIVATIVE; WART VIRUS VACCINE; CANCER VACCINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL EDUCATION; COLON CANCER; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; INTESTINE FLORA; LOW DRUG DOSE; LUNG CANCER; OVARY CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT PLANNING; TUMOR IMMUNOLOGY; UTERINE CERVIX CANCER; VACCINATION; NEOPLASMS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AROMATASE INHIBITORS; CANCER VACCINES; CHEMOPREVENTION; ESTROGEN RECEPTOR MODULATORS; HUMANS; METFORMIN; NEOPLASMS;

EID: 84928582571     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.12.006     Document Type: Review

References (80)

1. Ahn J., Sinha R., Pei Z., Dominianni C., Wu J., Shi J., Goedert J.J., Hayes R.B., Yang L. Human gut microbiome and risk for colorectal cancer. J.Natl. Cancer Inst. 2013, 105:1907-1911.
2. Albanes D., Heinonen O.P., Taylor P.R., Virtamo J., Edwards B.K., Rautalahti M., Hartman A.M., Palmgren J., Freedman L.S., Haapakoski J., Barrett M.J., Pietinen P., Malila N., Tala E., Liippo K., Salomaa E.R., Tangrea J.A., Teppo L., Askin F.B., Taskinen E., Erozan Y., Greenwald P., Huttunen J.K. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J.Natl. Cancer Inst. 1996, 88:1560-1570.
3. Alberts D.S., Martinez M.E., Roe D.J., Guillen-Rodriguez J.M., Marshall J.R., van Leeuwen J.B., Reid M.E., Ritenbaugh C., Vargas P.A., Bhattacharyya A.B., Earnest D.L., Sampliner R.E. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N.Engl. J. Med. 2000, 342:1156-1162.
4. Arber N., Eagle C.J., Spicak J., Racz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., Rosenstein R.B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A.G., Solomon S.D., Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N.Engl. J. Med. 2006, 355:885-895.
5. Baker S.G., Kramer B.S. Surrogate endpoint analysis: an exercise in extrapolation. J.Natl. Cancer Inst. 2013, 105:316-320.
6. Baron J.A., Cole B.F., Sandler R.S., Haile R.W., Ahnen D., Bresalier R., McKeown-Eyssen G., Summers R.W., Rothstein R., Burke C.A., Snover D.C., Church T.R., Allen J.I., Beach M., Beck G.J., Bond J.H., Byers T., Greenberg E.R., Mandel J.S., Marcon N., Mott L.A., Pearson L., Saibil F., van Stolk R.U. A randomized trial of aspirin to prevent colorectal adenomas. N.Engl. J. Med. 2003, 348:891-899.
7. Barrett-Connor E., Mosca L., Collins P., Geiger M.J., Grady D., Kornitzer M., McNabb M.A., Wenger N.K. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N.Engl. J. Med. 2006, 355:125-137.
8. Beatty P.L., Finn O.J. Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas. Ann. N. Y. Acad. Sci. 2013, 1284:52-56.
9. Beresford S.A., Johnson K.C., Ritenbaugh C., Lasser N.L., Snetselaar L.G., Black H.R., Anderson G.L., Assaf A.R., Bassford T., Bowen D., Brunner R.L., Brzyski R.G., Caan B., Chlebowski R.T., Gass M., Harrigan R.C., Hays J., Heber D., Heiss G., Hendrix S.L., Howard B.V., Hsia J., Hubbell F.A., Jackson R.D., Kotchen J.M., Kuller L.H., LaCroix A.Z., Lane D.S., Langer R.D., Lewis C.E., Manson J.E., Margolis K.L., Mossavar-Rahmani Y., Ockene J.K., Parker L.M., Perri M.G., Phillips L., Prentice R.L., Robbins J., Rossouw J.E., Sarto G.E., Stefanick M.L., Van H.L., Vitolins M.Z., Wactawski-Wende J., Wallace R.B., Whitlock E. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006, 295:643-654.
10. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Solomon S.D., Kim K., Tang J., Rosenstein R.B., Wittes J., Corle D., Hess T.M., Woloj G.M., Boisserie F., Anderson W.F., Viner J.L., Bagheri D., Burn J., Chung D.C., Dewar T., Foley T.R., Hoffman N., Macrae F., Pruitt R.E., Saltzman J.R., Salzberg B., Sylwestrowicz T., Gordon G.B., Hawk E.T. Celecoxib for the prevention of sporadic colorectal adenomas. N.Engl. J. Med. 2006, 355:873-884.
11. Bonanni B., Puntoni M., Cazzaniga M., Pruneri G., Serrano D., Guerrieri-Gonzaga A., Gennari A., Stella T.M., Galimberti V., Veronesi P., Johansson H., Aristarco V., Bassi F., Luini A., Lazzeroni M., Varricchio C., Viale G., Bruzzi P., Decensi A. Dual effect of metformin on breast Cancer proliferation in a randomized presurgical trial. J.Clin. Oncol. 2012, 30:2593-2600.
12. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Targher G., Alberiche M., Bonadonna R.C., Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998, 47:1643-1649.
13. Bosch F.X. Human papillomavirus: science and technologies for the elimination of cervical cancer. Expert Opin. Pharmacother. 2011, 12:2189-2204.
14. Burn J., Gerdes A.M., Macrae F., Mecklin J.P., Moeslein G., Olschwang S., Eccles D., Evans D.G., Maher E.R., Bertario L., Bisgaard M.L., Dunlop M.G., Ho J.W., Hodgson S.V., Lindblom A., Lubinski J., Morrison P.J., Murday V., Ramesar R., Side L., Scott R.J., Thomas H.J., Vasen H.F., Barker G., Crawford G., Elliott F., Movahedi M., Pylvanainen K., Wijnen J.T., Fodde R., Lynch H.T., Mathers J.C., Bishop D.T. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011, 378:2081-2087.
15. Cauley J.A., Norton L., Lippman M.E., Eckert S., Krueger K.A., Purdie D.W., Farrerons J., Karasik A., Mellstrom D., Ng K.W., Stepan J.J., Powles T.J., Morrow M., Costa A., Silfen S.L., Walls E.L., Schmitt H., Muchmore D.B., Jordan V.C. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat. 2001, 65:125-134.
16. Chan A.T., Manson J.E., Feskanich D., Stampfer M.J., Colditz G.A., Fuchs C.S. Long-term aspirin use and mortality in women. Arch. Intern. Med. 2007, 167:562-572.
17. Chang M.H. Prevention of hepatitis B virus infection and liver cancer. Recent Results Cancer Res. 2014, 193:75-95.
18. Cook N.R., Lee I.M., Gaziano J.M., Gordon D., Ridker P.M., Manson J.E., Hennekens C.H., Buring J.E. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005, 294:47-55.
19. Costantino J.P., Gail M.H., Pee D., Anderson S., Redmond C.K., Benichou J., Wieand H.S. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J.Natl. Cancer Inst. 1999, 91:1541-1548.
20. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
21. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev. Anticancer Ther. 2008, 8:1377-1385.
22. Cuzick J., Sestak I., Bonanni B., Costantino J.P., Cummings S., Decensi A., Dowsett M., Forbes J.F., Ford L., LaCroix A.Z., Mershon J., Mitlak B.H., Powles T., Veronesi U., Vogel V., Wickerham D.L. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013, 381:1827-1834.
23. Cuzick J., Sestak I., Forbes J.F., Dowsett M., Knox J., Cawthorn S., Saunders C., Roche N., Mansel R.E., von M.G., Bonanni B., Palva T., Howell A. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014, 383:1041-1048.
24. Cuzick J., Forbes J.F., Sestak I., Cawthorn S., Hamed H., Holli K., Howell A. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J.Natl. Cancer Inst. 2007, 99:272-282.
25. Decensi A., Bonanni B., Maisonneuve P., Serrano D., Omodei U., Varricchio C., Cazzaniga M., Lazzeroni M., Rotmensz N., Santillo B., Sideri M., Cassano E., Belloni C., Muraca M., Segnan N., Masullo P., Costa A., Monti N., Vella A., Bisanti L., D'Aiuto G., Veronesi U. A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. Ann. Oncol. 2013, 24:2753-2760.
26. Decensi A., Robertson C., Guerrieri-Gonzaga A., Serrano D., Cazzaniga M., Mora S., Gulisano M., Johansson H., Galimberti V., Cassano E., Moroni S.M., Formelli F., Lien E.A., Pelosi G., Johnson K.A., Bonanni B. Randomized double-blind 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J.Clin. Oncol. 2009, 27:3749-3756.
27. Decensi A., Robertson C., Viale G., Pigatto F., Johansson H., Kisanga E.R., Veronesi P., Torrisi R., Cazzaniga M., Mora S., Sandri M.T., Pelosi G., Luini A., Goldhirsch A., Lien E.A., Veronesi U. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J.Natl. Cancer Inst. 2003, 95:779-790.
28. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 2007, 7:684-700.
29. Dong L.M., Ulrich C.M., Hsu L., Duggan D.J., Benitez D.S., White E., Slattery M.L., Farin F.M., Makar K.W., Carlson C.S., Caan B.J., Potter J.D., Peters U. Vitamin D related genes, CYP24A1 and CYP27B1, and colon cancer risk. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2540-2548.
30. Finn O.J. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunol. Res. 2014, 2:708-713.
31. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., Bevers T.B., Kavanah M.T., Atkins J.N., Margolese R.G., Runowicz C.D., James J.M., Ford L.G., Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J.Natl. Cancer Inst. 2005, 97:1652-1662.
32. Flossmann E., Rothwell P.M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007, 369:1603-1613.
33. Gandini S., Boniol M., Haukka J., Byrnes G., Cox B., Sneyd M.J., Mullie P., Autier P. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer 2011, 128:1414-1424.
34. Gandini S., Gnagnarella P., Serrano D., Pasquali E., Raimondi S. Vitamin D receptor polymorphisms and cancer. Adv. Exp. Med. Biol. 2014, 810:69-105.
35. Gandini S., Puntoni M., Heckman-Stoddard B.M., Dunn B.K., Ford L., Decensi A., Szabo E. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev. Res. (Phila) 2014, 7:867-885.
36. Goodwin P.J., Stambolic V., Lemieux J., Chen B.E., Parulekar W.R., Gelmon K.A., Hershman D.L., Hobday T.J., Ligibel J.A., Mayer I.A., Pritchard K.I., Whelan T.J., Rastogi P., Shepherd L.E. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res. Treat. 2011, 126:215-220.
37. Goss P.E., Ingle J.N., Alés-Martinez J.E., Cheung A.M., Chlebowski R.T., Wactawski-Wende J., McTiernan A., Robbins J., Johnson K.C., Martin L.W., Winquist E., Sarto G.E., Garber J.E., Fabian C.J., Pujol P., Maunsell E., Farmer P., Gelmon K.A., Tu D., Richardson H. Exemestane for Breast-Cancer prevention in postmenopausal women. N.Engl. J. Med. 2011, 364:2381-2391.
38. Guerrieri-Gonzaga A., Lazzeroni M., Botteri E., Serrano D., Rotmensz N., Varricchio M.C., Cazzaniga M., Bollani G., Mora S., Montefrancesco C., Pruneri G., Viale G., Intra M., Galimberti V., Goldhirsch A., Bagnardi V., Bonanni B., Decensi A. Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study. Ann. Oncol. 2013, 24:1859-1866.
39. Herberman R.B., Pearce H.L., Lippman S.M., Pyenson B.S., Alberts D.S. Cancer chemoprevention and cancer preventive vaccines-a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need. Cancer Res. 2006, 66:11540-11549.
40. Hibler E.A., Jacobs E.T., Stone A.D., Sardo C.L., Galligan M.A., Jurutka P.W. Associations between vitamin D-binding protein isotypes, circulating 25(OH)D levels, and vitamin D metabolite uptake in colon cancer cells. Cancer Prev. Res. (Phila) 2014, 7:426-434.
41. Hueman M.T., Dehqanzada Z.A., Novak T.E., Gurney J.M., Woll M.M., Ryan G.B., Storrer C.E., Fisher C., McLeod D.G., Ioannides C.G., Ponniah S., Peoples G.E. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin. Cancer Res. 2005, 11:7470-7479.
42. Itzkowitz S.H., Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G7-17.
43. Kelloff G.J., Boone C.W., Crowell J.A., Steele V.E., Lubet R., Doody L.A. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J.Cell. Biochem. Suppl. 1994, 19:1-9.
44. Kimura T., McKolanis J.R., Dzubinski L.A., Islam K., Potter D.M., Salazar A.M., Schoen R.E., Finn O.J. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev. Res. (Phila) 2013, 6:18-26.
45. Kuerer H.M., Buzdar A.U., Mittendorf E.A., Esteva F.J., Lucci A., Vence L.M., Radvanyi L., Meric-Bernstam F., Hunt K.K., Symmans W.F. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 2011, 117:39-47.
46. Lazzeroni M., Serrano D. Potential use of vaccines in the primary prevention of breast cancer in high-risk patients. Breast Care (Basel) 2012, 7:281-287.
47. Lazzeroni M., Serrano D., Dunn B.K., Heckman-Stoddard B.M., Lee O., Khan S., Decensi A. Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug. Breast Cancer Res. 2012, 14:214.
48. Lippman S.M., Klein E.A., Goodman P.J., Lucia M.S., Thompson I.M., Ford L.G., Parnes H.L., Minasian L.M., Gaziano J.M., Hartline J.A., Parsons J.K., Bearden J.D., Crawford E.D., Goodman G.E., Claudio J., Winquist E., Cook E.D., Karp D.D., Walther P., Lieber M.M., Kristal A.R., Darke A.K., Arnold K.B., Ganz P.A., Santella R.M., Albanes D., Taylor P.R., Probstfield J.L., Jagpal T.J., Crowley J.J., Meyskens F.L., Baker L.H., Coltman C.A. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301:39-51.
49. Marchesi J.R., Dutilh B.E., Hall N., Peters W.H., Roelofs R., Boleij A., Tjalsma H. Towards the human colorectal cancer microbiome. PLoS ONE 2011, 6:e20447.
50. Martino S., Cauley J.A., Barrett-Connor E., Powles T.J., Mershon J., Disch D., Secrest R.J., Cummings S.R. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J.Natl. Cancer Inst. 2004, 96:1751-1761.
51. Meyskens F.L., Szabo E. How should we move the field of chemopreventive agent development forward in a productive manner?. Recent Results Cancer Res. 2005, 166:113-124.
52. Mittendorf E.A., Clifton G.T., Holmes J.P., Schneble E., van E.D., Ponniah S., Peoples G.E. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol 2014, 25:1735-1742.
53. Mohammed A., Janakiram N.B., Brewer M., Vedala K., Steele V.E., Rao C.V. Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis. Neoplasia 2013, 15:481-490.
54. Moysich K.B., Menezes R.J., Ronsani A., Swede H., Reid M.E., Cummings K.M., Falkner K.L., Loewen G.M., Bepler G. Regular aspirin use and lung cancer risk. BMC Cancer 2002, 2:31.
55. PAGE I.H. Low cholesterol-low fat diets in prevention and treatment of atherosclerosis. Med. Clin. North Am. 1952, 36:195-199.
56. Peoples G.E., Gurney J.M., Hueman M.T., Woll M.M., Ryan G.B., Storrer C.E., Fisher C., Shriver C.D., Ioannides C.G., Ponniah S. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005, 23:7536-7545.
57. Powles T.J., Ashley S., Tidy A., Smith I.E., Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J.Natl. Cancer Inst. 2007, 99:283-290.
58. Raimondi S., Johansson H., Maisonneuve P., Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009, 30:1170-1180.
59. Ratnasinghe L.D., Graubard B.I., Kahle L., Tangrea J.A., Taylor P.R., Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004, 24:3177-3184.
60. Rothwell P.M., Fowkes F.G., Belch J.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
61. Rothwell P.M., Wilson M., Elwin C.E., Norrving B., Algra A., Warlow C.P., Meade T.W. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010, 376:1741-1750.
62. Sandler R.S., Halabi S., Baron J.A., Budinger S., Paskett E., Keresztes R., Petrelli N., Pipas J.M., Karp D.D., Loprinzi C.L., Steinbach G., Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N.Engl. J. Med. 2003, 348:883-890.
63. Schatzkin A., Lanza E., Corle D., Lance P., Iber F., Caan B., Shike M., Weissfeld J., Burt R., Cooper M.R., Kikendall J.W., Cahill J. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N.Engl. J. Med. 2000, 342:1149-1155.
64. Sharma A., Koldovsky U., Xu S., Mick R., Roses R., Fitzpatrick E., Weinstein S., Nisenbaum H., Levine B.L., Fox K., Zhang P., Koski G., Czerniecki B.J. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 2012, 118:4354-4362.
65. Sorensen H.T., Lash T.L., Rothman K.J. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 2006, 44:1075-1082.
66. Sporn M.B. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 1976, 36:2699-2702.
67. Streicher S.A., Yu H., Lu L., Kidd M.S., Risch H.A. Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 2014, 23:1254-1263.
68. Thun M.J., Namboodiri M.M., Calle E.E., Flanders W.D., Heath C.W. Aspirin use and risk of fatal cancer. Cancer Res. 1993, 53:1322-1327.
69. Toprak N.U., Yagci A., Gulluoglu B.M., Akin M.L., Demirkalem P., Celenk T., Soyletir G. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin. Microbiol. Infect. 2006, 12:782-786.
70. Trabert B., Ness R.B., Lo-Ciganic W.H., Murphy M.A., Goode E.L., Poole E.M., Brinton L.A., Webb P.M., Nagle C.M., Jordan S.J., Risch H.A., Rossing M.A., Doherty J.A., Goodman M.T., Lurie G., Kjaer S.K., Hogdall E., Jensen A., Cramer D.W., Terry K.L., Vitonis A., Bandera E.V., Olson S., King M.G., Chandran U., nton-Culver H., Ziogas A., Menon U., Gayther S.A., Ramus S.J., Gentry-Maharaj A., Wu A.H., Pearce C.L., Pike M.C., Berchuck A., Schildkraut J.M., Wentzensen N. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J.Natl. Cancer Inst. 2014, 106. djt431.
71. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., Bevers T.B., Fehrenbacher L., Pajon E.R., Wade J.L., Robidoux A., Margolese R.G., James J., Lippman S.M., Runowicz C.D., Ganz P.A., Reis S.E., McCaskill-Stevens W., Ford L.G., Jordan V.C., Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727-2741.
72. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., Bevers T.B., Fehrenbacher L., Pajon E.R., Wade J.L., Robidoux A., Margolese R.G., James J., Runowicz C.D., Ganz P.A., Reis S.E., Caskill-Stevens W., Ford L.G., Jordan V.C., Wolmark N. Update of the national surgical adjuvant breast and bowelproject study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev. Res. (Phila) 2010, 3:696-706.
73. Wald N.J., Morris J.K., Law M.R. Aspirin in the prevention of cancer. Lancet 2011, 377:1649-1652.
74. Wang X., Allen T.D., May R.J., Lightfoot S., Houchen C.W., Huycke M.M. Enterococcus faecalis induces aneuploidy and tetraploidy in colonic epithelial cells through a bystander effect. Cancer Res. 2008, 68:9909-9917.
75. Waters E.A., Cronin K.A., Graubard B.I., Han P.K., Freedman A.N. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol. Biomarkers Prev. 2010, 19:443-446.
76. Wong N.D., Cupples L.A., Ostfeld A.M., Levy D., Kannel W.B. Risk factors for long-term coronary prognosis after initial myocardial infarction: the Framingham Study. Am. J. Epidemiol. 1989, 130:469-480.
77. Wu S., Rhee K.J., Albesiano E., Rabizadeh S., Wu X., Yen H.R., Huso D.L., Brancati F.L., Wick E., McAllister F., Housseau F., Pardoll D.M., Sears C.L. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 2009, 15:1016-1022.
78. Wu X., Lippman S.M. An intermittent approach for cancer chemoprevention. Nat. Rev. Cancer 2011, 11:879-885.
79. Zhou L., Zhang X., Chen X., Liu L., Lu C., Tang X., Shi J., Li M., Zhou M., Zhang Z., Xiao L., Yang M. GC Glu416Asp and Thr420Lys polymorphisms contribute to gastrointestinal cancer susceptibility in a Chinese population. Int. J. Clin. Exp. Med. 2012, 5:72-79.
80. Zittermann A., Iodice S., Pilz S., Grant W.B., Bagnardi V., Gandini S. Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am. J. Clin. Nutr. 2012, 95:91-100.